Äéêáéþìáôá áóèåíþí

Ç ÷þñá ìáò ôï 1992 äéáôõðþíåé óå Íüìï ( 2071 / Üñèñï 47) "ôá Äéêáéþìáôá ôïõ Íïóïêïìåéáêïý Áóèåíïýò".

Í. 2071 ÖÅÊ 123/92 A'

¢ñèñï 47

Ôá äéêáéþìáôá ôïõ íïóïêïìåéáêïý áóèåíïýò

1. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá ðñïóåããßóåùò óôéò õðçñåóßåò ôïõ íïóïêïìåßïõ, ôéò ðëÝïí êáôÜëëçëåò ãéá ôç öýóç ôçò áóèÝíåéáò ôïõ.

2. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá ôçò ðáñï÷Þò öñïíôßäáò ó´ áõôüí ìå ôïí ïöåéëüìåíï óåâáóìü óôçí áíèñþðéíç áîéïðñÝðåéá ôïõ. ÁõôÞ ç öñïíôßäá ðåñéëáìâÜíåé ü÷é ìüíï ôçí åí ãÝíåé Üóêçóç ôçò éáôñéêÞò êáé ôçò íïóçëåõôéêÞò, áëëÜ êáé ôéò ðáñáúáôñéêÝò õðçñåóßåò, ôçí êáôÜëëçëç äéáìïíÞ, ôçí êáôÜëëçëç ìåôá÷åßñéóç êáé ôçí áðïôåëåóìáôéêÞ äéïéêçôéêÞ êáé ôå÷íéêÞ åîõðçñÝôçóç.

3. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá íá óõãêáôáôåèåß Þ íá áñíçèåß êÜèå äéáãíùóôéêÞ Þ èåñáðåõôéêÞ ðñÜîç ðïõ ðñüêåéôáé íá äéåíåñãçèåß óå áõôüí. Óå ðåñßðôùóç áóèåíïýò ìå ìåñéêÞ Þ ðëÞñç äéáíïçôéêÞ áíéêáíüôçôá, ç Üóêçóç áõôïý ôïõ äéêáéþìáôïò ãßíåôáé áðü ôï ðñüóùðï ðïõ êáôÜ íüìï åíåñãåß ãéá ëïãáñéáóìü ôïõ.

4. Ï áóèåíÞò äéêáéïýôáé íá æçôÞóåé íá ðëçñïöïñçèåß ü,ôé áöïñÜ óôçí êáôÜóôáóÞ ôïõ.

5. Ôï óõìöÝñïí ôïõ áóèåíïýò åßíáé êáèïñéóôéêü êáé åîáñôÜôáé áðü ôçí ðëçñüôçôá êáé ôçí áêñßâåéá ôùí ðëçñïöïñéþí ðïõ ôïõ äßíïíôáé. Ç ðëçñïöüñçóç ôïõ áóèåíïýò ðñÝðåé íá ôïõ åðéôñÝøåé íá ó÷çìáôßóåé ðëÞñç åéêüíá ôùí éáôñéêþí, êïéíùíéêþí êáé ïéêïíïìéêþí ðáñáìÝôñùí ôçò êáôáóôÜóåùò ôïõ êáé íá ëáìâÜíåé áðïöÜóåéò ï ßäéïò Þ íá ìåôÝ÷åé óôç ëÞøç áðïöÜóåùí, ðïõ åßíáé äõíáôüí íá ðñïäéêÜóïõí ôç ìåôÝðåéôá æùÞ ôïõ.

6. Ï áóèåíÞò Þ ï åêðñüóùðüò ôïõ óå ðåñßðôùóç åöáñìïãÞò ôçò ðáñ. 3, Ý÷åé ôï Äéêáßùìá íá ðëçñïöïñçèåß, ðëÞñùò êáé åê ôùí ðñïôÝñùí, ãéá ôïõò êéíäýíïõò ðïõ åíäÝ÷åôáé íá ðáñïõóéáóèïýí Þ íá ðñïêýøïõí åî áöïñìÞò åöáñìïãÞò óå áõôüí áóõíÞèùí Þ ðåéñáìáôéêþí äéáãíùóôéêþí êáé èåñáðåõôéêþí ðñÜîåùí. Ç åöáñìïãÞ ôùí ðñÜîåùí áõôþí óôïí áóèåíÞ ëáìâÜíåé ÷þñá ìüíï ýóôåñá áðü óõãêåêñéìÝíç óõãêáôÜèåóç ôïõ ßäéïõ. Ç óõãêáôÜèåóç áõôÞ ìðïñåß íá áíáêëçèåß áðü ôïí áóèåíÞ áíÜ ðÜóá óôéãìÞ.

7. Ï áóèåíÞò ðñÝðåé íá áéóèÜíåôáé ôåëåßùò åëåýèåñïò óôçí áðüöáóç ôïõ, íá äå÷èåß Þ íá áðïññßøåé, êÜèå óõíåñãáóßá ôïõ ìå óêïðü ôçí Ýñåõíá Þ ôçí åêðáßäåõóÞ. Ç óõãêáôÜèåóÞ ôïõ ãéá ôõ÷üí óõììåôï÷Þ ôïõ, åßíáé äéêáßùìÜ ôïõ êáé ìðïñåß íá áíáêëçèåß áíÜ ðÜóá óôéãìÞ.

8. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá óôï ìÝôñï êáé óôéò ðñáãìáôéêÝò óõíèÞêåò ðïõ åßíáé äõíáôüí, ðñïóôáóßáò ôçò éäéùôéêÞò ôïõ æùÞò. Ï áðüññçôïò ÷áñáêôÞñáò ôùí ðëçñïöïñéþí êáé ôïõ ðåñéå÷ïìÝíïõ ôùí åããñÜöùí ðïõ ôïí áöïñïýí, ôïõ öáêÝëïõ ôùí éáôñéêþí óçìåéþóåùí êáé åõñçìÜôùí, ðñÝðåé íá åßíáé åããõçìÝíïò.

9. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá ôïõ óåâáóìïý êáé ôçò áíáãíùñßóåùò óå áõôüí ôùí èñçóêåõôéêþí êáé éäåïëïãéêþí ôïõ ðåðïéèÞóåùí.

10. Ï áóèåíÞò Ý÷åé ôï äéêáßùìá íá ðáñïõóéÜóåé Þ íá êáôáèÝóåé áñìïäßùò äéáìáñôõñßåò êáé åíóôÜóåéò êáé íá ëÜâåé ðëÞñç ãíþóç ôùí åð' áõôþí åíåñãåéþí êáé áðïôåëåóìÜôùí.


ÏÑÃÁÍÁ ÐÑÏÓÔÁÓÉÁÓ ÄÉÊÁÉÙÌÁÔÙÍ ÁÓÈÅÍÙÍ

Ôï 1997 ìå ôï Íüìï 2519 êáèéåñþíïíôáé ôá ¼ñãáíá Ðñïóôáóßáò ÄéêáéùìÜôùí ôùí Áóèåíþí êáé áñ÷ßæåé ç ðñïþèçóç êáé äéÜäïóç ôïõ èåóìïý.

Óýìöùíá ìå ôï Íüìï áõôü, óõíéóôþíôáé óôï Õðïõñãåßï Õãåßáò:

á) Ç ÁõôïôåëÞò Õðçñåóßá Ðñïóôáóßáò ôùí ÄéêáéùìÜôùí ôùí Áóèåíþí ç ïðïßá õðÜãåôáé áð' åõèåßáò óôï Ãåíéêü ÃñáììáôÝá ôïõ Õðïõñãåßïõ êáé

â) Ç ÅðéôñïðÞ ÅëÝã÷ïõ Ðñïóôáóßáò ÄéêáéùìÜôùí ôùí Áóèåíþí

ðïõ Ý÷ïõí ôçí êåíôñéêÞ åõèýíç ðáñáêïëïýèçóçò êáé áíÜðôõîçò ôïõ èåóìïý.

Äýï ÷ñüíéá ìåôÜ, ìå ôï Íüìï 2716/99, äçìéïõñãÞèçêáí êáé ëåéôïõñãïýí óå êÜèå Íïóïêïìåßï:

á) Ãñáöåßï Åðéêïéíùíßáò ìå ôïí Ðïëßôç êáé

â) ÅðéôñïðÞ ÐñïÜóðéóçò ÄéêáéùìÜôùí ôïõ Ðïëßôç


ÓõíÞãïñïò ôïõ Ðïëßôç

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò èåóðßóôçêå ìå ôïí Í.3293/2004. ÊáôÜ ôçí Üóêçóç ôùí áñìïäéïôÞôùí ôïõ ó÷åôéêÜ ìå ôá äéêáéþìáôá ôçò õãåßáò, ðñüíïéáò êáé êïéíùíéêÞò áëëçëåããýçò åéóçãåßôáé ðñïò ôï áñìüäéï Õðïõñãåßï ìÝôñá ãéá ôçí áðïêáôÜóôáóç êáé ðñïóôáóßá ôùí äéêáéùìÜôùí ôïõ ðïëßôç.

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò åíóùìáôþèçêå óôçí áíåîÜñôçôç Áñ÷Þ ôïõ Óõíçãüñïõ ôïõ Ðïëßôç ðïõ Þäç ðáñÝ÷åé äùñÝáí ôéò õðçñåóßåò ôïõ óå üëïõò ôïõò ðïëßôåò - ÷ñÞóôåò ôùí äçìüóéùí õðçñåóéþí õãåßáò.

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò åîåôÜæåé ôç íïìéìüôçôá áôïìéêþí äéïéêçôéêþí ðñÜîåùí Þ ðáñáëåßøåùí öïñÝùí ôïõ óõóôÞìáôïò Õãåßáò êáôüðéí õðïâïëÞò áíáöïñÜò áðü ôïõò èéãüìåíïõò ðïëßôåò, ¸ëëçíåò Þ áëëïäáðïýò. Ðáñåìâáßíåé, åöüóïí ðñïçãïõìÝíùò ïé åíäéáöåñüìåíïé Ý÷ïõí Þäç áðåõèõíèåß óôçí åìðëåêüìåíç õðçñåóßá õãåßáò.

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò äéáìåóïëáâåß óå õðïèÝóåéò ðïõ áöïñïýí ôï Õðïõñãåßï Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò, ôçí ÔïðéêÞ êáé Íïìáñ÷éáêÞ Áõôïäéïßêçóç, ôïõò Áóöáëéóôéêïýò Ïñãáíéóìïýò êáé ôá Ôáìåßá, ôá Íïóïêïìåßá, ôá Øõ÷éáôñåßá, ôá ÊÝíôñá Õãåßáò, ôá ÐåñéöåñåéáêÜ êáé ÁãñïôéêÜ Éáôñåßá, ôï Å.Ê.Á.Â. êëð.

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò áíôéìåôùðßæåé Ýíá åõñý öÜóìá ðñïâëçìÜôùí ðïõ áíôéìåôùðßæåé ï ÷ñÞóôçò õðçñåóéþí õãåßáò, üðùò:
Ðáñï÷Þ áêáôÜëëçëçò ðåñßèáëøçò, äçëáäÞ ðñßèáëøçò ðïõ äåí óõíÜäåé ìå ôïõò êáíüíåò ôçò åðéóôÞìçò êáé ôïõò Êþäéêåò Äåïíôïëïãßáò ôùí ÅðáããåëìÜôùí Õãåßáò êáé èßãåé ôçí áîéïðñÝðåéá ôïõ áóèåíÞ.

¢íéóç ìåôá÷åßñçóç êáé äéáêñßóåéò óå âÜñïò ôïõ ëüãù åèíéêüôçôáò, öõëÞò, ïéêïíïìéêÞò êáôÜóôáóçò Þ åßäïõò áóèåíåßáò. Ãéá ðáñÜäåéãìá, ï ÓõíÞãïñïò åîåôÜæåé ðåñéðôþóåéò äéáêñßóåùí óå âÜñïò áëëïäáðþí, óå âÜñïò áóèåíþí ðïõ ðÜó÷ïõí áðü ôï óýíäñïìï åðßêôçôçò áíïóïëïãéêÞò áíåðÜñêåéáò (AIDS) êëð.

Äõó÷Ýñåéá óôçí ðñüóâáóç ôïõ áóèåíÞ óå êáôÜëëçëåò õðçñåóßåò õãåßáò. Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò åîåôÜæåé áíáöïñÝò ðïõ ó÷åôßæïíôáé ìå ôçí ïñãÜíùóç ìïíÜäùí õãåßáò, ôçí áóöáëÞ êáé Ýãêáéñç ìåôáöïñÜ ôùí áóèåíþí óå áõôÝò êáé ôçí åðÜñêåéÜ ôïõò óå êôéñéáêÞ õðïäïìÞ, õëéêïýò ðüñïõò êáé áíèñþðéíï äõíáìéêü. Ãéá ðáñÜäåéãìá, ï ÓõíÞãïñïò åîåôÜæåé áíáöïñÝò ðïõ Ý÷ïõí ùò áíôéêåßìåíï ôçí áðïõóßá åöçìåñåýïíôïò éáôñïý, ôçí êáèõóôÝñçóç ôïõ ÅÊÁ íá ìåôáöÝñåé áóèåíÞ êëð.

ÐáñÜëåéøç åíçìÝñùóçò ãéá ôçí êáôÜóôáóç ôçò õãåßáò, ôç èåñáðåßá êáé ôï êüóôïò áõôÞò. Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò äÝ÷åôáé áíáöïñÝò ðïëéôþí ðïõ äåí åíçìåñþèçêáí êáôÜëëçëá ãéá ôç äéÜãíùóç ôçò áóèÝíåéÜò ôïõò, ôá óôÜäéá èåñáðåßáò êáé ôï êüóôïò áõôÞò Þ õðïâëÞèçêáí åí áãíïßá ôïõò óå éáôñéêÝò ðñÜîåéò ìå õøçëü êßíäõíï åðéðëïêþí ãéá ôçí õãåßá ôïõò.

ÄéåíÝñãåéá éáôñéêþí ðñÜîåùí ÷ùñßò ôçí ðñïçãïýìåíç óõãêáôÜèåóç. Ï ðïëßôçò ìðïñåß íá ðñïóöýãåé óôïí ÓõíÞãïñï ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò üôáí äåí ãßíåôáé óåâáóôü ôï äéêáéùìÜ ôïõ íá äå÷èåß Þ íá áñíçèåß ôçí ðñïôåéíüìåíç èåñáðåßá.

Ìç ôÞñçóç ôïõ éáôñéêïý áðïññÞôïõ ðïõ áöïñÜ ôéò åìðéóôåõôéêÝò ðëçñïöïñßåò ðïõ ï ßäéïò ï áóèåíÞò ðáñÝ÷åé Þ åêåßíåò ðïõ áðïêáëýðôïíôáé êáôÜ ôçç äéÜñêåéá ôçò ðåñßèáëøçò êáé êáôÜ ôçí Üóêçóç ôùí éáôñéêþí ðñÜîåùí.

¢ñíçóç ôçò ðñüóâáóçò óå Ýããñáöá ôïõ éáôñéêïý öáêÝëëïõ. Óôçí áñìïäéüôçôá ôïõ ÓõíÞãïñïõ ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò åìðßðôåé ï Ýëåã÷ïò ôçò ôÞñçóçò éáôñéêïý öáêÝëëïõ áðü ôá íïóçëåõôéêÜ éäñýìáôá, ôçò ðëçñüôçôáò áõôïý, ôçò åîáóöÜëéóçò ôïõ áðïññÞôïõ ôùí ðëçñïöïñéþí Ýíáíôé ôñßôùí êáèþò êáé ôçò ðñüóâáóçò ôïõ áóèåíïýò Þ ôùí åîïõóéïäïôçìÝíùí áðü áõôüí ðñïóþðùí óôïí öÜêåëëï. Ï ÓõíÞãïñïò Ý÷åé Þäç åîåôÜóåé ðëÞèïò ó÷åôéêþí áíáöïñþí. Óõ÷íÜ áóèåíåßò Þ íïìßìùò åîïõóéïäïôïýìåíá ôñßôá ðñüóùðá æçôïýí ôç ÷ïñÞãçóç óôïé÷åßùí ôïõ éáôñéêïý öáêÝëïõ ôïõò êáé ðñïóêñïýïõí óôéò áðïññéðôéêÝò áðáíôÞóåéò ôùí íïóçëåõôéêþí éäñõìÜôùí, ôá ïðïßá åóöáëìÝíùò åðéêáëïýíôáé ëüãïõò éáôñéêïý áðïññÞôïõ.

ÅóöáëìÝíç åöáñìïãÞ ôïõ íüìïõ óå ðåñéðôþóåéò íïóïêïìåéáêÞò Þ åîùíïóïêïìåéáêÞò ðåñßèáëøçò óôçí áëëïäáðÞ êáé ìç íüìéìç Üñíçóç ôùí áóöáëéóôéêþ ïñãáíéóìþí íá áðïäþóïõí ôçí ó÷åôéêÞ äáðÜíç.

Ìç íüìéìç ÷ñÝùóç áóèåíþí óå ðåñéðôþóåéò Ýêôáêôçò åéóáãùãÞò óå éãéùôéêÜ èåñáðåõôÞñéá.

ÐñïâëÞìáôá óôç ÷ïñÞãçóç ðáñï÷þí áóèÝíåéáò áðü ôïõò áóöáëéóôéêïýò ïñãáíéóìïýò, üðùò áðüäïóç äáðáíþí, åíçìÝñùóç áóöáëéóìÝíùí ãéá ôéò ðñïâëåðüìåíåò äéáäéêáóßåò, ðñïèåóìßåò, äéêáéïëïãçôéêÜ îëð. Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò Ý÷åé åîåôÜóåé áíáöïñÝò ðïõ Ý÷ïõí ùò áíôéêåßìåíï áðïöÜóåéò ôùí áóöáëéóôéêþí ïñãáíéóìþí êáé óôçñßæïíôáé óå áíáéôéïëüãçôåò ãíùìáôåýóåéò ôùí õãåéïíïìéêþí åðéôñïðþí. ¢ëëï ðáñÜäåéãìá áðïôåëïýí ïé áíáöïñÝò ìå áíôéêåßìåíï ôçí áäéêáéïëüãçôç êáé âëáðôéêÞ ãéá ôçí õãåßá êáèõóôÝñçóç óôçí Ýêäïóç êáé êïéíïðïßçóç åñãáóôçñéáêþí åîåôÜóåùí.

ÐñïâëÞìáôá ôùí åðáããåëìáôéþí õãåßáò ôüóï ôïõ Å.Ó.Õ. üóï êáé ôùí áóöáëéóôéêþí ïñãáíéóìþí, óôçí ðñüóâáóç êáé Üóêçóç ôïõ åðáããÝëìáôüò ôïõò.

ÈÝìáôá äçìüóéáò õãåßáò, äçëáäÞ oñãÜíùóçò ôùí éáôñéêþí êáé íïóçëåõôéêþí õðçñåóéþí êáé áíÜðôõîçò êïéíùíéêþí ìç÷áíéóìþí ðïõ äéáóöáëßæïõí ôçí ðñüëçøç íïóçìÜôùí, ôçí ðñïóôáóßá, ôçí áýîçóç ôïõ ðñïóäüêéìïõ åðéâßùóçò êáé ôç âåëôßùóç ôçò ðïéüôçôáò æùÞò. Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò åîåôÜæåé ð.÷. èÝìáôá äéá÷åßñçóçò ôùí íïóïêïìåéáêþí áðïâëÞôùí.

Ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò äåí åßíáé áñìüäéïò:

  • ÅÜí Ý÷ïõí ðåñÜóåé ðåñéóóüôåñïé áðü 6 ìÞíåò áðü ôüôå ðïõ ï ðïëßôçò ðëçñïöïñÞèçêå ôçí åðßìá÷ç ðáñÜíïìç ðñÜîç Þ ðáñÜëåéøç.
  • Ãéá ðñÜîåéò ôùí äéêáóôéêþí áñ÷þí, ôïõ Íïìéêïý Óõìâïõëßïõ ôïõ ÊñÜôïõò, ôùí áíåîÜñôçôùí áñ÷þí, ôùí èñçóêåõôéêþí íïìéêþí ðñïóþðùí äçìïóßïõ äéêáßïõ.
  • Ãéá ðñÜîåéò Õðïõñãþí êáé Õöõðïõñãþí, ùò ðñïò ôç äéá÷åßñçóç ôçò ðïëéôéêÞò ëåéôïõñãßáò.
  • Ãéá õðïèÝóåéò ðïõ åêêñåìïýí åíþðéïí äéêáóôçñßùí.
  • Ãéá õðïèÝóåéò ðïõ áíáöÝñïíôáé óôçí õðçñåóéáêÞ êáôÜóôáóç ôïõ ðñïóùðéêïý ôùí õðçñåóéþí õãåßáò, åêôüò åÜí ðñüêåéôáé ãéá ðñïóëÞøåéò Þ êñßóåéò éáôñþí êëÜäïõ ôïõ Å.Ó.Õ., êáèþò êáé ãéá ðñïóëÞøåéò éáôñþí óå áóöáëéóôéêïýò ïñãáíéóìïýò êáé ôáìåßá.
  • Åðßóçò, ï ÓõíÞãïñïò ôçò Õãåßáò êáé ÊïéíùíéêÞò Áëëçëåããýçò äåí ðáñÝ÷åé íïìéêÞ óõìâïõëåõôéêÞ Þ åêðñïóþðçóç, ïýôå ÷ïñçãåß áðïæçìéþóåéò óå ðåñéðôþóåéò éáôñéêþí ëáèþí.


Ðþò åðéêïéíùíþ ìå ôïí ÓõíÞãïñï ôïõ Ðïëßôç

×áëêïêïíäýëç 17, Ô.Ê. 10432 ÁèÞíá

ÄåõôÝñá Ýùò ÐáñáóêåõÞ 08.30 - 14.00 êáé ÔåôÜñôç ìå äéåõñõìÝíï ùñÜñéï 08.30 - 16.30

Ôçë: (+30) 213 1306 600

Öáî: (+30) 213 1306 800

Åðéêïéíùíßá ìå email



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò